Serum vs FNA:.

Slides:

Advertisements

Similar presentations

Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.

Advertisements

AZD6244 Detection of BRAF Mutations in Tumour and Serum of Patients with Advanced Melanoma Dr Ruth Board CMGS Spring Scientific Conference March 26 th.

The highlight of resistance mechanism of targeted therapy on clinical therapy Zuhua Chen Dep. of GI oncology.

A B Supplementary Figure S1. T790M CTC PointMan genotyping assay. (A) Test characteristics of PointMan CTC T790M genotyping assay. The assay was validated.

May 29 - June 2, 2015 TIGER-X: Rociletinib Activity in EGFR T790M Mutant NSCLC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* *CCO.

CtDNA NGS testing identified a high-level MET amplification (copy number of 53.6 in circulation) (Figure 1A). The test was repeated on a second tube of.

Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.

Anna Buder Institute of Cancer Research Department of Medicine I Medical University of Vienna Liquid Biopsies Analysis of circulating cell-free tumor-DNA.

Emerging Genomic Technologies: Extending the Application of Genomics to Prediction, Diagnosis, Monitoring, and Early Detection Luis A. Diaz, M.D. Johns.

Big Data in Genomics, Diagnostics, and Precision Medicine

Drug Development 2017 ctDNA: Tool of the Future?

Plasma Droplet Digital PCR for Detection of EGFR and KRAS Mutations in Patients With Advanced Nonsquamous NSCLC Slideset on: Sacher AG, Paweletz C, Dahlberg.

Fig 1A. Patient enrollment flow chart

Patient Case 1 Patient Case 1: PET/CT Scan.

Crystal digital PCR for detection and quantification of circulating EGFR mutations in advanced non-small cell lung cancer Cécile Jovelet Postdocoral fellow.

Challenges in RAS Wild-Type mCRC

Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

The New Taxonomy of Metastatic NSCLC and Physician Treatment Based on Pathologic and Molecular Characteristics The New Taxonomy of Metastatic Non-Small.

Fundamental Concepts in the Diagnosis of Advanced NSCLC

Assessing the Impact: New Data in T790+ NSCLC

New Patient Journeys in Non-small cell lung cancer

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

Updates in Lung Cancer: Insights From Vienna

Proof-of-concept clinical studies validating AZD9291 as a mutant-selective EGFR kinase T790M inhibitor. Proof-of-concept clinical studies validating AZD9291.

Updates and Perspectives on Third-Generation EFGR TKIs in Advanced NSCLC.

Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R

Monitoring EGFR mutation status in Non-small cell lung cancer (NSCLC) patients using circulating Tumour DNA (ctDNA). Matthew Smith Molecular Pathology.

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

T790M Mutation-Positive NSCLC: A Multidisciplinary Case Conference

EGFR Inhibitors in Advanced NSCLC: Who, When, and Why?

More Than Meets the Eye.

Lung Cancer Screening. The Pulmonologist’s Role in Improving Personalized Diagnosis and Treatment of NSCLC.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib Chao-Chi Ho, MD, PhD, Wei-Yu Liao, MD, PhD, Chih-An Lin, Jin-Yuan.

Moving Care Forward in Advanced NSCLC

EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

Breast Cancer Statistics

Figure 1 The dynamic nature of resistance mechanisms can be

Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer Suzanne Jenkins, DPhil, James C-H.

Immune Checkpoint Inhibitors in Lung Cancer

Clinical applications of CTCs and ctDNA as liquid biopsy for personalized medicine. Clinical applications of CTCs and ctDNA as liquid biopsy for personalized.

Understanding the Updated Guidelines for ALK Testing in NSCLC

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

Practical Strategies to Guideline-Recommended Biomarker Testing in NSCLC.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Multidisciplinary Management in Non-Small Cell Lung Cancer (NSCLC)

Optimizing Characterization of NSCLC Through Specialty Collaboration

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

Jamie A. Saxon, PhD, Lynette M. Sholl, MD, Pasi A. Jänne, MD, PhD

New Insights on Treatment Strategies for mCRC:

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

The Nurse View: Spotlight on EGFR-Mutated NSCLC

Finding the Right Sequence in Patients With EGFR-Mutated NSCLC

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?

Current Status of Biomarkers for Immune Checkpoint Inhibitors

Detection of somatic mutations in plasma allows for non-invasive real time therapy response monitoring of lung cancer patients José Carlos Machado.

Next-Generation Sequencing and ctDNA

Plasma and tissue EGFR allele analyses.

Location of common clinically relevant mutations in EGFR

Prevalence of germline T790M.

Updates in Best Practices in Non-Small Cell Lung Cancer

A, study design for measuring the feasibility, concordance, and accuracy of a plasma-based cfDNA sequencing test compared with biopsy-based sequencing.

Response and resistance to savolitinib and osimertinib in a patient with EGFR-mutant NSCLC harboring MET amplification. Response and resistance to savolitinib.

Presentation transcript:

Serum vs FNA:

Activity Goals

Liquid Biopsy in Lung Cancer

Applications of Liquid Biopsy

Meta-Analysis of Blood vs Tissue Biopsy for EGFR Mutations

Genotyping Methodologies ctDNA and cfDNA

Questions Clinicians Should Be Asking About Liquid Biopsy Assays

Case Study Discussion

Guidelines for Biomarker Testing

Case Discussion (cont)

EGFR Resistance and T790M

AURA: Osimertinib (AZD9291) in Treatment-Naïve EGFR-Mutated NSCLC

Plasma Testing for T790M Has Good Sensitivity and Likely Good Specificity

TIGER-X: Phase 1/2 Study of Rociletinib in Advanced NSCLC

Concordance of Plasma and Tissue Biopsy

Conclusions and Clinical Pearls